

Electronic Acknowledgement Receipt

EFS ID:	10217319
Application Number:	10788426
International Application Number:	
Confirmation Number:	4965
Title of Invention:	NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS
First Named Inventor/Applicant Name:	Jacques Dumas
Customer Number:	23599
Filer:	Richard J. Traverso/Ashley Weber
Filer Authorized By:	Richard J. Traverso
Attorney Docket Number:	BAYER-0044
Receipt Date:	02-JUN-2011
Filing Date:	01-MAR-2004
Time Stamp:	16:53:39
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	Foreign Reference	N20-JP01-200254Apatentandabstract.pdf	1368216 67b9155c5b533e1fa09f567f5243a3254864 a4cb	no	32

Warnings:

Information:

2	Foreign Reference	N21- JP01-259360patentandabstract .pdf	972277 5e45921676dd9462efba5b443157a0398d3 6a938	no	21
Warnings:					
Information:					
3	Foreign Reference	N22- JP02-022650patentandabstract .pdf	586045 44bdbed3363ebcefcb45dbbdff369f85ed49 a16b	no	12
Warnings:					
Information:					
4	Foreign Reference	N23- JP02-023337patentandabstract .pdf	2453615 803e5c004e9ea246d8328558dcc092b6e9f 90d69	no	43
Warnings:					
Information:					
5	Foreign Reference	N24- JP02-035450patentandabstract .pdf	933198 69c55cdaf4064e348c30b6d6a4d7773b423 4ed56	no	19
Warnings:					
Information:					
6	Foreign Reference	N25- JP2-105146patentandabstract .pdf	1007468 77bf8181adb323c4644c8328b9d67972acf 4a63c	no	19
Warnings:					
Information:					
7	Foreign Reference	N26- JP21-08048Apatentandabstract .pdf	1047095 21286dd33b70a7ea41003a544506c63cf20 04e76	no	21
Warnings:					
Information:					
8	Foreign Reference	N27- JP21-50840Apatentandabstract .pdf	1852752 38472f31806e3206f9f849fd488dc7ebf8ff5f 3c	no	35
Warnings:					
Information:					
9	Foreign Reference	N28-JP353247A.pdf	2256105 012cb53d3e876465f7665c2035c396dab0a e41b2	no	53
Warnings:					
Information:					
10	Foreign Reference	N29- JP3-144634patentandabstract .pdf	1215788 d31ae3dac4c710e28e05f2917063022a6cb b4ac4	no	27
Warnings:					
Information:					

11	Foreign Reference	N30-JP3-198049patentandabstract.pdf	1523798 02c7bbce234808a581f783e13e3d7cc6dfda e2a0	no	32
Warnings:					
Information:					
12	Foreign Reference	N31-JP6-75172B2.pdf	2947143 ff615b8bc1cf1392537d3365029cfab950 613a	no	83
Warnings:					
Information:					
13	Foreign Reference	N32-JP08-031841A.pdf	418830 9037b5b95683fc76d881682787921d3985e 22073	no	6
Warnings:					
Information:					
14	Foreign Reference	N33-JP10-306078a.pdf	1848801 edc240d08a98bcbeb12ca8697b90c2ee676 f7b03	no	102
Warnings:					
Information:					
15	Foreign Reference	O1-LB-6124.pdf	5408189 55fa363a87f53716853fae9f1ec62c32a389c 97e	no	120
Warnings:					
Information:					
16	Non Patent Literature	P7-Avuruch.pdf	815295 51bf24d8c0b69a2e06dd49805760c27eeeaa 27fa4	no	5
Warnings:					
Information:					
17	Non Patent Literature	P9a-BakaetalAreviewoflatestclincal.pdf	881500 202bd76ecc9ef8ff22ad8af30596ae06ee8 cd4	no	10
Warnings:					
Information:					
18	Non Patent Literature	P10-BALANTLPETAL-METABOLICCONSIDERATIONS.PDF	2630313 b0b0ccb1be945d2031ffa466e3328f7e6666 be74	no	35
Warnings:					
Information:					
19	Non Patent Literature	P17-BERGESTEPHENMLYLEDHIGHLEYANDDONALDCMONKHOUSEPHARMACEUTICALSALTS.pdf	2779981 24d4aa003e1a22d855791f541adbf10ad2 6540d	no	19
Warnings:					
Information:					

20	Non Patent Literature	P22-Martin-Blanco-p38MAPK.pdf	212665 9b6d919dbea7158136b66ceac569b372bb c71781	no	9
Warnings:					
Information:					
21	Non Patent Literature	P23-Foussard-Blanpin-ComparitivePharmacodynamic study.pdf	324049 7673a4217ac16d6b526a4a4745c2b0a443d d47d8	no	12
Warnings:					
Information:					
22	Non Patent Literature	P25-BOLLAGETAL-RAFPathwayInhibitors.pdf	570524 124e6f8014aca1cad11e69dc70a8191a0db 759e8	no	6
Warnings:					
Information:					
23	Non Patent Literature	P26-BoltonetalOncogeneDirectedApproachesinCancerChemotherapy.pdf	1322358 3d861bca2a7bd236e2a3b2f6a645b585b7b 14221	no	10
Warnings:					
Information:					
24	Non Patent Literature	P28a-BoyerSmallMoleculeInhibitorsoffKDR.pdf	2453975 41b072c857def1b0cfea15ffe6e34f525fb78 b9c	no	28
Warnings:					
Information:					
25	Non Patent Literature	P50-COPERETCHRISTOPHEETALASIMPLEANDEFFICIENTMETHODFORTHEPREPARATIONOF.PDF	246666 35fca5e45b2ed4f201526da7d439399eb46 b8989	no	4
Warnings:					
Information:					
26	Non Patent Literature	P53a-CrumplnhibitionofRafkinaseAML.pdf	129960 f7afec875758c734aa4383c5be17b8479616 4f0b	no	2
Warnings:					
Information:					
27	Non Patent Literature	P57-DaumTheInsandOutsofRafKinases.pdf	923597 b8dd50c7c5aaa180ac3cbf8bc229fec15b7 9e90	no	7
Warnings:					
Information:					
28	Non Patent Literature	P66-DumasProtienKinaseInhibitorsfromtheUreaClass.pdf	750454 2832fb0f9b242eda77836f4466046fb88d49 bb03	no	10
Warnings:					
Information:					

29	Non Patent Literature	P67Dumas2000.pdf	155092 65503af91fe34f1770aa80bce8fd24554e98 7a7e	no	4
Warnings:					
Information:					
30	Non Patent Literature	P68-Dumas1-Phenyl-5-pyrazolylUreasPotentandSelectivep38KinaseInhibitors.pdf	281356 b405c6dc9d8fc3a99fe9ed8fc2d0a307762 6ef7	no	4
Warnings:					
Information:					
31	Non Patent Literature	P68a-DumasJGrowthFactorReceptorKinase.pdf	1180537 5ab3c8d78ca3ff17e71d451932b8882e8d5 db5bb	no	12
Warnings:					
Information:					
32	Non Patent Literature	P68b-DumasJProteinKinaseInhibitors.pdf	1745212 336fe85d2801d11dff2b37eab00aead41fb0 4774	no	25
Warnings:					
Information:					
33	Non Patent Literature	P166-LyonsDiscoveryofaNovelRafKinaseInhibitor.pdf	816218 8eea8beb1e240da3dce3c172182060977aa 09dd3	no	8
Warnings:					
Information:					
34	Non Patent Literature	P68c-DumasetalOral.pdf	83425 994573c4463b20ad0b6b03fbe2903613eb5 1aecc	no	1
Warnings:					
Information:					
35	Non Patent Literature	P69-DumasRecentDevelopmentsinDiscoveryofProteinKinaseInhibitorsfromtheUreaClass.pdf	1279668 8b39b27fa2be83f26cfbf1619185835d3a8 7a33	no	17
Warnings:					
Information:					
36	Non Patent Literature	P70-DUMASETAL-SynthesisOrallyActivep38.pdf	367020 e90c2ec8b7d97c4c012703ed321c73565ae 2ff89	no	4
Warnings:					
Information:					
37	Non Patent Literature	P107-GURA0009C02-SystemsIdentifyingNewDrugs.pdf	475596 e2c27bcc239e0292c834584f165ec4d4e96 a552	no	5
Warnings:					
Information:					

38	Non Patent Literature	P147-KuboetalSynthesisandStructureactivity.pdf	168474 3a3ce5677bbffaa8331f1a4d78bc9de74f1c 53cf	no	1
Warnings:					
Information:					
39	Non Patent Literature	P149-KUMAR-ET-AL-DrugsTargetedProteinKinases-1.pdf	1326625 d7973ef9cb6c196a013562059fc939a6a794 b8c4	no	14
Warnings:					
Information:					
40	Non Patent Literature	P224-ReganPyrazoleUrea-BasedInhibitorsofp38MAPKinaseFormLeadCompoundtoClinicalCandidate.pdf	1709151 bd0f3cf673fd0f61918fa7233d3f914b02b1b 853	no	15
Warnings:					
Information:					
41	Non Patent Literature	P248-SmithDiscoveryofHeterocyclicUreasasaNewClassofRafKinaseInhibitors.pdf	355827 07d6281e045dd31deea0ead92df3665fa 3ff65	no	4
Warnings:					
Information:					
42	Non Patent Literature	P249-SMITHETAL-RecentAdvancesRAF.pdf	38048 80e0b2f242fc280afe3ba0c3b2cd1416c59b fa02	no	1
Warnings:					
Information:					
43	Non Patent Literature	P276-Thaimattam3D-QSA.pdf	962868 0db4ae09edc28039bdb61ec5a693cf1eccd d1690	no	11
Warnings:					
Information:					
44	Non Patent Literature	P278-ThompsonRecentProgressinTargetingtheRaf-MEK-ERKPathwaywithInhibitorsinCancerDrugDiscovery.pdf	656952 ffe349fad7fadb94da688b16ce09be0543cc 15cd	no	8
Warnings:					
Information:					
45	Non Patent Literature	P294-WilsonTheStructuralBasisfortheSpecificityofPyridinylimidazole.pdf	723222 aed136d4a8a0a5dea95d94fc1eaf1048252 3e6f	no	9
Warnings:					
Information:					
46	Non Patent Literature	P312-XP001152608KuboetalSynthesisandStructureActivity.pdf	60045 db3a9672220d2f7f8ced89d86cb24dab17 58d65	no	1
Warnings:					
Information:					

47	Non Patent Literature	P313-RiedletalPotentRafKinaseInhibitorsfromtheDiphenyl.pdf	43951 5482a07d7acbf10d71951c23c8902ee4b53 4f5d2	no	1
Warnings:					
Information:					
48	Non Patent Literature	P315-AbstractofDE3305866A.pdf	54521 e06a4cd0464b897b0b7928e46c099759535 0fe17	no	1
Warnings:					
Information:					
49	Non Patent Literature	P316-AbstractofEP4931A.pdf	56012 e15a8733a3a9546835f3bc24a5db852b0d5 9eb21	no	1
Warnings:					
Information:					
50	Non Patent Literature	P317-AbstractofEP16371.pdf	70897 98c114658c3375a1b5f74cb5cd64160fb7 878a	no	1
Warnings:					
Information:					
51	Non Patent Literature	P318-AbstractofEP16371A.pdf	52264 5f89269a7554352838f4790e9cf1d47231e7 6657	no	1
Warnings:					
Information:					
52	Non Patent Literature	P319-AbstractofEP0116932.pdf	98741 28b762aba1e0fbcab3b8d10bcb43351e707 a77c2	no	2
Warnings:					
Information:					
53	Non Patent Literature	P320-AbstractofEP0116932A1.pdf	98161 7a4ed0aafab57000340b881e9cfed53ceeb3 bb7c	no	2
Warnings:					
Information:					
54	Non Patent Literature	P321-AbstractofEP0202538A1.pdf	175567 63d3ac8a52862521c596bf6f930669a40745 28e0	no	3
Warnings:					
Information:					
55	Non Patent Literature	P322-AbstractofEP0202538A1.pdf	219857 918e908d0e4c7b138aeb731ac38b750d294 b9ed6	no	4
Warnings:					
Information:					

56	Non Patent Literature	P323-AbstractofEP0405233A1.pdf	62671 2feb9bf3ac09b9f24f81e80eafcdcd286f02d1 ce3	no	2
Warnings:					
Information:					
57	Non Patent Literature	P324-AbstractofEP0405233A1.pdf	46936 f15c74416c9bb6b43e8527c449b6b326595 c2835	no	1
Warnings:					
Information:					
58	Non Patent Literature	P325-AbstractofEP676395A.pdf	189634 64dfd7bbc990c531a95f11cadb20acfad28c 9d98	no	3
Warnings:					
Information:					
59	Non Patent Literature	P68d-DumasJRafKinaseInhibitors.pdf	230963 0b3a99998e8e47c9c7c8c40071de96d08a5 6aea6	no	2
Warnings:					
Information:					
60	Non Patent Literature	P326-AbstractofEP0676395A2.pdf	46706 b3d570a5f06e57b1f4ac3d26006d9243ddc 3940e	no	1
Warnings:					
Information:					
Total Files Size (in bytes):				53712874	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					